Literature DB >> 18413571

Functional imaging in Parkinson disease.

R Nandhagopal1, Martin J McKeown, A Jon Stoessl.   

Abstract

OBJECTIVE: Functional imaging techniques represent useful tools to assess in vivo the neurochemical alterations and functional connectivity in Parkinson disease (PD). Here, the authors review the various approaches and potential application of these imaging techniques to the study of PD.
METHOD: Radiotracer imaging using dopaminergic markers facilitates assessment of pre- and postsynaptic nigrostriatal integrity, while imaging with other appropriate radiotracers explores nondopaminergic neurotransmitter function, local metabolism, blood flow, and mechanisms potentially related to disease progression and pathogenesis. Activation studies using functional MRI detect blood oxygen level dependent signal, as an indirect marker of neuronal activity. RESULT: Functional imaging techniques have been applied to infer the potential role of inflammation and other factors in etiopathogenesis as well as to study compensatory and regulatory mechanisms in early PD and subclinical disease in genetic forms of PD. Imaging studies also help to understand the neurobiological basis of motor and nonmotor complications. Recent reports suggest a role for striatal dopaminergic transmission in modulating neurobehavioral processes including the placebo effect in PD. Although functional imaging has been employed to monitor disease progression, the discordance between clinical outcome and imaging measures after therapeutic interventions precludes their use as surrogate end points in clinical trials. Beyond these limitations and potential challenges, imaging techniques continue to find wide application in the study of PD.
CONCLUSION: Functional imaging can provide meaningful insights into mechanisms underlying various aspects of motor and nonmotor dysfunction in Parkinson disease and the role of striatal dopaminergic transmission in behavioral processes beyond motor control. These modalities hold promise to study the preclinical phase and to elucidate further the benefits and complications of surgical interventions and the utility of neuroprotective strategies.

Entities:  

Mesh:

Year:  2008        PMID: 18413571     DOI: 10.1212/01.wnl.0000310432.92489.90

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  25 in total

Review 1.  Neuroimaging in Parkinson's disease.

Authors:  A Jon Stoessl
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

Review 2.  Axon degeneration in Parkinson's disease.

Authors:  Robert E Burke; Karen O'Malley
Journal:  Exp Neurol       Date:  2012-01-18       Impact factor: 5.330

Review 3.  Differences between conventional and nonconventional MRI techniques in Parkinson's disease.

Authors:  A Baglieri; M A Marino; R Morabito; G Di Lorenzo; P Bramanti; S Marino
Journal:  Funct Neurol       Date:  2013 Apr-May

Review 4.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 5.  [Imaging of genetic aspects of Parkinson's disease].

Authors:  N Brüggemann; J Vegt; C Klein; H R Siebner
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

6.  Low nigrostriatal reserve for motor parkinsonism in nonhuman primates.

Authors:  Samer D Tabbal; Linlin Tian; Morvarid Karimi; Christopher A Brown; Susan K Loftin; Joel S Perlmutter
Journal:  Exp Neurol       Date:  2012-07-24       Impact factor: 5.330

Review 7.  Parkinsonian syndromes.

Authors:  Francesco Federico; Domenico Maria Mezzapesa; Marco Petruzzellis
Journal:  Neurol Sci       Date:  2008-10       Impact factor: 3.307

8.  PET imaging in rats to discern temporal onset differences between 6-hydroxydopamine and tau gene vector neurodegeneration models.

Authors:  Ronald L Klein; Robert D Dayton; Tracee L Terry; Chris Vascoe; John J Sunderland; Kerrie H Tainter
Journal:  Brain Res       Date:  2009-02-10       Impact factor: 3.252

9.  Cortical Thinning and Cognitive Impairment in Parkinson's Disease without Dementia.

Authors:  Lijun Zhang; Ming Wang; Nicholas W Sterling; Eun-Young Lee; Paul J Eslinger; Daymond Wagner; Guangwei Du; Mechelle M Lewis; Young Truong; F DuBois Bowman; Xuemei Huang
Journal:  IEEE/ACM Trans Comput Biol Bioinform       Date:  2018 Mar-Apr       Impact factor: 3.710

10.  L-dopa medication in Parkinson's disease restores activity in the motor cortico-striatal loop but does not modify the cognitive network.

Authors:  Thomas Jubault; Laura Monetta; Antonio P Strafella; Anne-Louise Lafontaine; Oury Monchi
Journal:  PLoS One       Date:  2009-07-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.